Algeria Highlights from a Scientific Meeting Organized by Pierre Fabre Laboratories in Algeria
The scientific meeting organized by Pierre Fabre Laboratories brought together 81 healthcare professionals, including oncologists and hospital pharmacists, to discuss advances in cancer treatment, evolving clinical recommendations, and strategies to improve patient care.
Over the past several years, oncology has undergone a profound transformation. Advances in molecular oncology, targeted therapies, immunotherapy, and antibody–drug conjugates have progressively changed the way we understand and treat cancer.
Against this backdrop of therapeutic innovation, one question remains particularly relevant: What is the role of chemotherapy in modern oncology?
This question was at the center of the scientific meeting, held in a triplex format connecting healthcare professionals across Algeria’s Central, Eastern, and Western regions to discuss evolving therapeutic strategies in oncology.
Molecular characterization of tumors has enabled the identification of actionable genetic alterations, paving the way for targeted therapies. Advances in tumor immunology have led to the development of immune checkpoint inhibitors, while targeted monoclonal antibodies and antibody–drug conjugates have expanded treatment options through more selective therapeutic approaches.
A Therapeutic Revolution That Has Transformed the Oncology Landscape
For several decades, cytotoxic chemotherapy has been one of the main pillars of systemic cancer treatment.
Its development has considerably improved the prognosis of many malignancies, both in curative settings and in advanced disease. Anthracyclines, taxanes, platinum compounds, fluoropyrimidines, gemcitabine, and many other agents continue to be part of the oncologist’s everyday therapeutic arsenal.
However, the landscape has changed profoundly.
Molecular characterization of tumors has made it possible to identify genetic alterations that may serve as therapeutic targets. Advances in tumor immunology have led to the development of immune checkpoint inhibitors. Monoclonal antibodies and antibody-drug conjugates have contributed to improving the selectivity of therapeutic interventions.
This evolution has led to a new approach to cancer treatment: treatment should be tailored not only to the organ of origin, but also to the biological characteristics of the tumor and the patient.
Has Chemotherapy Become Obsolete?
The emergence of innovative treatments has not resulted in the disappearance of chemotherapy. Rather, it has redefined its role.
In many cancers, chemotherapy remains an essential component of treatment, either as monotherapy or in combination with other therapeutic agents, depending on the tumor type, disease stage, and treatment objectives.
In breast cancer, chemotherapy continues to play an important role, particularly in triple-negative breast cancer, where it remains a cornerstone of treatment and may be combined with immunotherapy in appropriately selected patients.
In lung, gastrointestinal, gynecological, urological, and hematological malignancies, cytotoxic agents also retain important indications, sometimes in combination with immunotherapy or targeted therapies.
Thus, the question is no longer simply:
“Chemotherapy or innovative therapy?”
It has become:
“Which therapeutic strategy for which patient, at what point, and with what objective?”
From Monotherapy to Combination Therapy
One of the most important developments in modern oncology has been the increasing use of therapeutic combinations.
Depending on the tumor type and clinical setting, chemotherapy may be combined with immunotherapy, targeted therapies, or monoclonal antibodies. Antibody–drug conjugates represent another important therapeutic development, although their combination with conventional chemotherapy is not routinely established across all cancer types.
These combinations are not simply intended to add treatments together. Rather, they are based on a biological and clinical rationale: targeting different mechanisms involved in tumor growth and progression to improve treatment outcomes.
In selected clinical settings, chemotherapy can achieve rapid tumor reduction, while targeted therapies act on specific molecular alterations and immunotherapy enhances antitumor immune responses.
This complementarity helps explain why chemotherapy continues to have an important role in the era of precision medicine.
Conclusion
In the era of innovative therapies, chemotherapy continues to occupy an important place in the oncologist’s therapeutic arsenal. However, its role has evolved: it is now integrated into a strategy that is more precise, more personalized, and increasingly based on combination approaches.
A central message emerging from the discussions was that the future of oncology will not be defined by an opposition between chemotherapy and innovation, but by their rational integration into personalized treatment strategies.
The true therapeutic revolution will be our ability to identify, for each patient, the right treatment, at the right time, and in the right sequence, while maintaining as central objectives not only disease control, but also quality of life and survival.
